Odyssey Therapeutics, Inc. Common Stock (ODTX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Odyssey Therapeutics, Inc. Common Stock (ODTX) is listed on Nasdaq, where it has traded since May 8, 2026.
- Listed On
- Nasdaq
- Listed Since
- May 8, 2026
- Market Cap
- $986M
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 55 institutions reported holding ODTX, with 34.8 million shares worth $651.4 million in aggregate. The largest reported holder was FMR, with 5.2 million shares worth $96.9 million. Of the 5 largest holders listed below, all 5 opened new positions in ODTX during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 5,179,262 | $97M | New position |
| SR One Capital Management | 3,794,883 | $71M | New position |
| Tpg GP a | 3,690,146 | $69M | New position |
| Lightspeed Management Company, | 3,608,443 | $68M | New position |
| Orbimed Advisors | 3,001,198 | $56M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ODTX?
Odyssey Therapeutics, Inc. Common Stock (ODTX) is listed on Nasdaq, where it has traded since May 8, 2026.
Who are the largest institutional holders of ODTX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ODTX were FMR, SR One Capital Management and Tpg GP a.
How many institutions own ODTX?
55 institutions reported a position in ODTX for the quarter ended June 30, 2026, worth $651.4 million in total.
Did institutions buy or sell ODTX last quarter?
Of the 5 largest reported holders, all 5 opened new positions in ODTX during the quarter. Every reported holder and its change is on the SentiSense ownership page for ODTX.
Every reported institutional holder, plus insider and congressional trades in ODTX, on SentiSense.